ShoreTel, Inc. Shares Climb Up On Better Than Expected Revenue Numbers
ShoreTel, Inc. (SHOR), a business communication solutions company yesterday reported their fiscal third quarter financial results. ShoreTel reported a loss of $2.9 million for the third quarter. ShoreTel reported third quarter adjusted earnings of $0.01 per share with revenues of $87.7 million which beat analyst expectations of $84.5 million. ShoreTel, Inc. CEO’s Comments “Total revenue, profitability […]
Morning Call For Thursday, April 27
OVERNIGHT MARKETS AND NEWS Jun E-mini S&Ps (ESM17 +0.17%) this morning are little changed, up +0.06%, after Preisident Trump ruled out a withdrawal from NAFTA. European stocks are down -0.40% ahead of today’s ECB meeting and press conference from ECB President Draghi that may provide clues as to when thee ECB may begin to exit […]
Dow Jones Industrial Average Doesn’t Know How To React To Trump Tax Plan
Wednesday was a big day for the United States. It was the day that the Donald Trump tax plan, or at least a brief overview of what the Trump administration plans to accomplish, was released. The goal of the tax plan is ultimately to stimulate growth in the United States economy. While the Dow started […]
Trading Apple Ahead Of Earnings
Apple (AAPL) is set to report second-quarter earnings this coming Tuesday. The drop in demand for the iPhone business will hit the quarter hard. The forecast for the next few quarters might come in weaker than expected as well. The good news is that the company has its services business to fall back on. Demand […]
More Short-Term Uncertainty As Stocks Get Close To Record High
Briefly: In our opinion, speculative short positions are favored (with stop-loss at 2,410, and profit target at 2,200, S&P 500 index). Our intraday outlook is bearish, and our short-term outlook is bearish. Our medium-term outlook remains neutral, following S&P 500 index breakout above last year’s all-time high: Intraday outlook (next 24 hours): bearish Short-term outlook (next […]
Okta Headed For Another Stock Boost From Quiet Period Expiration
Event Overview The quiet period will expire for Okta (Nasdaq:OKTA), on May 2, 2015. On that date, restrictions preventing underwriters from recommending or reporting on the deal will be lifted. Underwriters tend to release reports as soon as restrictions are lifted and these reports most often are positive. Our firm has studied price movement around […]
It’s Different This Time…
Just recently, Wealth Management had an interesting interview with Jeremy Grantham in which Jeremy suggests the “rules have changed” for value investors. To wit: “The market was extremely well-behaved from 1935 until 2000. It was an orderly world in which to be a value manager: there was mean reversion. If a value manager was patient, he was in heaven. The market outperformed when […]
Liquidity: The Most Important Fundamental
I’m sure you’ve heard analysts, financial pundits, and other babbling heads yabber on and on about how these markets don’t reflect the “fundamentals”. They’ve ranted non-stop about how the fundamentals prove that a bear market is around the corner. They’ve raved about valuations being stretched and how stocks will collapse any day now… If you’ve been taking investment advice […]
Stocks Dazed After Trump NAFTA Flop, Tax Plan Disappointment; ECB Looms
European shares are lower, pressured by disappointing results by Deutsche Bank and ending a six-session gain, as Asian equities and S&P futures were little changed after a record-setting rally in world stocks which pushed the MSCI World index to over $50 trillion yesterday, fizzled after Trump released unconvincing tax cut plans prompting traders to “sell […]
Premarket Biotech Digest – ANTM May Increase Premium, IPXL Receives FDA Approval, ZTS Receives EC Nod
Top Pick of the Day: MNOV MediciNova Inc. (MNOV) announced that it has received positive preliminary results from a six-month open-label extension period evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis. ALS patients who completed both the six-month treatment period in the Phase 2 clinical trial and the six-month open-label extension period (n=31) experienced significantly higher […]
